Roche Holding AG (OTCMKTS: RHHBY) To Announce Solutions for Helping Tackle Major Neurological Disorders at EAN-2021
With an aim to make a major breakthrough in the neurosciences sphere, Roche Holding AG (OTCMKTS: RHHBY) will present the latest development in the clinical trials of Evrysdi and Enspryng medications at the annual meeting of the European Academy of Neurology (EAN). The 4-day virtual meet is scheduled to start on June 19, 2021, and will see the company demonstrate new data to help in understanding some rare neurological disorders.
Levi Garraway, Chief Medical Officer of Roche, confirmed the news and said that the data will help expand the neurosciences portfolio of the company and help by changing the lives of patients suffering from major neurological conditions. The data will be presented for neurological problems including Spinal Muscular Atrophy (SMA), Neuromyelitis Optica Spectrum Disorder (NMOSD), Multiple Sclerosis (MS), Alzheimer Disease (AD), and Parkinson Disease (PD).
As per data, over 3,000 SMA patients have been successfully treated in trials of Evrysdi, and it is approved in over 42 US and EU countries. The FIREFISH, SUNFISH, JEWELFISH, and RAINBOWFISH trials have all indicated the safety and efficacy of the medication in SMA patients.
For patients suffering from Neuromyelitis Optica Spectrum Disorder (NMOSD), the company will present data to reduce the relapse risk of the disease in adults. The data will show how safe the Enspryng medication is for NMOSD and concomitant autoimmune diseases (CAIDs) patients. Enspryng has the approval of 24 countries until now, and the data will help reach newer milestones in the European markets.
The data presented for patients with Multiple Sclerosis (MS) will demonstrate the efficacy of Ocrevus in improving productivity and reduction in psychological side-effects of MS.
To tackle Alzheimer’s Disease (AD), Roche will showcase the miraculous findings of RG6102 from clinical trials conducted for patients having a moderate disease.
For people who have Parkinson’s Disease (PD), the company will present data on trials of prasinezumab antibody. The drug use ensured a reduction in motor signs in PD patients, and its safety was also proved.